Algeta

Activities: Manufacturing Ingredients Research & Development

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its...
  2. £20m Scottish oligonucleotide manufacturing innovation centre now under construction The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's...
  3. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within...
  4. Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Pharmaceutical

Thomas Ramdahl appointed as Managing Director of Algeta

Bayer has completed the acquisition of the Norwegian developer of cancer drugs
Research & Development

Algeta appoints Chief Scientific Officer

Dr Andreas Menrad takes responsibility for the Norwegian company\'s research strategy
Manufacturing

Algeta opens commercial production facility for Xofigo in Norway

The plant for the manufacture of the cancer treatment is based at the Institute for Energy Technology (IFE) in Norway
Manufacturing

Cobra Biologics and Algeta sign monoclonal antibody manufacturing agreement

Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies

Norwegian cancer therapeutics developer appoints president

Jeffrey Albers takes up the role at Algeta US
Regulatory

Anticancer agent – radium-223 chloride

Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development

Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227

Norwegian firm to create pipeline of cancer-destroying drugs
Subscribe now